Characteristics | Total population (N = 1,158) | No-MACCE (N = 808) | MACCE (N = 350) | p value |
---|---|---|---|---|
Demographics | ||||
Age (years) | 64.5 ± 8.0 | 64.3 ± 8.0 | 64.7 ± 7.8 | 0.445 |
Male, n (%) | 872 (75.3%) | 618 (76.5%) | 254 (72.6%) | 0.156 |
BMI (kg/m2) | 26.19 ± 3.19 | 26.02 ± 3.04 | 26.59 ± 3.49 | 0.008 |
SBP (mmHg) | 130 ± 17 | 129 ± 16 | 132 ± 18 | 0.031 |
DBP (mmHg) | 75 ± 11 | 74 ± 10 | 76 ± 11 | 0.060 |
Heart rate (bpm) | 67 ± 10 | 67 ± 10 | 68 ± 11 | 0.069 |
Current smoking, n (%) | 273 (23.6%) | 182 (22.5%) | 91 (26.0%) | 0.201 |
Family history of CAD, n (%) | 106 (9.2%) | 68 (8.4%) | 38 (10.9%) | 0.186 |
Medical histories | ||||
Hypertension, n (%) | 837 (72.3%) | 578 (71.5%) | 259 (74.0%) | 0.389 |
Dyslipidemia, n (%) | 1,152 (99.5%) | 805 (99.6%) | 347 (99.1%) | 0.374 |
T2DM, n (%) | 533 (46.0%) | 358 (44.3%) | 175 (50.0%) | 0.074 |
Prior MI, n (%) | 557 (48.1%) | 377 (46.7%) | 180 (51.4%) | 0.136 |
Prior PCI, n (%) | 249 (21.5%) | 168 (20.8%) | 81 (23.1%) | 0.371 |
Prior stroke, n (%) | 147 (12.7%) | 103 (12.7%) | 44 (12.6%) | 0.934 |
PAD, n (%) | 111 (9.6%) | 76 (9.4%) | 35 (10.0%) | 0.752 |
HF, n (%) | 74 (6.4%) | 52 (6.4%) | 22 (6.3%) | 0.924 |
CKD, n (%) | 38 (3.3%) | 22 (2.7%) | 16 (4.6%) | 0.105 |
Clinical diagnosis | 0.446 | |||
UA, n (%) | 1,008 (87.0%) | 710 (87.9%) | 298 (85.1%) | |
NSTEMI, n (%) | 115 (9.9%) | 75 (9.3%) | 40 (11.4%) | |
STEMI, n (%) | 35 (3.0%) | 23 (2.8%) | 12 (3.4%) | |
Laboratory measurements | ||||
WBC (x109/L) | 6.82 ± 1.72 | 6.80 ± 1.69 | 6.86 ± 1.79 | 0.549 |
Hb (g/L) | 141.69 ± 15.81 | 142.52 ± 15.34 | 139.77 ± 16.70 | 0.009 |
PLT (x109/L) | 204.72 ± 56.08 | 204.66 ± 54.73 | 204.87 ± 59.15 | 0.955 |
hs-CRP (mg/L) | 1.24 (0.55, 3.23) | 1.08 (0.51, 2.77) | 1.81 (0.69, 4.04) | < 0.001 |
Creatinine (𝝁mmol/L) | 77.52 ± 19.95 | 76.56 ± 18.04 | 79.75 ± 23.64 | 0.024 |
eGFR (mL/min/1.73m2) | 90.43 ± 22.60 | 91.09 ± 21.51 | 88.91 ± 24.90 | 0.155 |
TG (mmol/L) | 1.66 ± 0.81 | 1.63 ± 0.80 | 1.72 ± 0.85 | 0.088 |
TC (mmol/L) | 3.99 ± 1.01 | 3.92 ± 0.97 | 4.16 ± 1.06 | < 0.001 |
LDL-C (mmol/L) | 2.36 ± 0.86 | 2.30 ± 0.84 | 2.49 ± 0.90 | < 0.001 |
HDL-C (mmol/L) | 1.01 ± 0.23 | 1.01 ± 0.23 | 1.01 ± 0.24 | 0.639 |
FBG (mmol/L) | 7.14 ± 3.01 | 6.92 ± 2.90 | 7.65 ± 3.19 | < 0.001 |
HbA1c (%) | 6.76 ± 1.34 | 6.74 ± 1.33 | 6.80 ± 1.36 | 0.544 |
TyG index | 8.98 ± 0.61 | 8.94 ± 0.60 | 9.08 ± 0.64 | < 0.001 |
LVEF (%) | 59 ± 8 | 59 ± 8 | 58 ± 8 | 0.311 |
GRACE risk score | 99 ± 34 | 99 ± 33 | 100 ± 36 | 0.518 |
Angiographic results | ||||
LM disease, n (%) | 358 (30.9%) | 253 (31.3%) | 105 (30.0%) | 0.713 |
Multivessel disease, n (%) | 1,059 (94.8%) | 739 (94.4%) | 320 (95.8%) | 0.325 |
Number of LIMA, n (%) | 1 (1, 1) | 1 (1, 1) | 1 (1, 1) | 0.233 |
Number of SVG, n (%) | 2 (1, 3) | 2 (1, 3) | 2 (1, 3) | 0.584 |
CTO, n (%) | 1,058 (91.5%) | 737 (91.2%) | 321 (92.2%) | 0.565 |
Thrombotic disease, n (%) | 35 (3.0%) | 24 (3.0%) | 11 (3.1%) | 0.875 |
In-stent restenosis, n (%) | 101 (8.7%) | 76 (9.4%) | 25 (7.2%) | 0.215 |
PCI outcomes | ||||
Target vessel territory | ||||
Native vessel, n (%) | 1,038 (89.6%) | 738 (91.3%) | 300 (85.7%) | 0.004 |
LM, n (%) | 141 (12.2%) | 108 (13.4%) | 33 (9.4%) | |
LAD, n (%) | 284 (24.5%) | 205 (25.4%) | 79 (22.6%) | |
LCX, n (%) | 389 (33.6%) | 263 (32.5%) | 126 (36.0%) | |
RCA, n (%) | 549 (47.4%) | 390 (48.3%) | 159 (45.4%) | |
Graft vessel, n (%) | 182 (15.7%) | 115 (14.2%) | 67 (19.1%) | 0.035 |
LIMA, n (%) | 4 (0.3%) | 3 (0.4%) | 1 (0.3%) | |
SVG, n (%) | 178 (15.4%) | 112 (13.9%) | 66 (18.9%) | |
Target vessel selection, n (%) | 0.015 | |||
Only native vessel | 976 (84.3%) | 693 (85.8%) | 283 (80.9%) | |
Only graft vessel | 120 (10.4%) | 70 (8.7%) | 50 (14.3%) | |
Both native and graft vessels | 62 (5.4%) | 45 (5.6%) | 17 (4.9%) | |
PTCA, n (%) | 114 (9.8%) | 77 (9.5%) | 37 (10.6%) | 0.585 |
DCB application, n (%) | 41 (3.5%) | 33 (4.1%) | 8 (2.3%) | 0.128 |
BMS implantation, n (%) | 2 (0.2%) | 1 (0.1%) | 1 (0.3%) | 0.513 |
DES implantation, n (%) | 1,027 (99.8%) | 728 (99.9%) | 299 (99.7%) | 0.498 |
Number of treated lesions | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 0.235 |
Number of stents | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 0.487 |
Interval time from CABG to PCI (years) | 6.3 ± 4.4 | 6.2 ± 4.3 | 6.5 ± 4.5 | 0.220 |
PCI success, n (%) | 1,024 (88.4%) | 724 (89.6%) | 300 (85.7%) | 0.057 |
Medications at discharge | ||||
DAPT, n (%) | 1,140 (98.4%) | 793 (98.1%) | 347 (99.1%) | 0.207 |
ACEI/ARB, n (%) | 592 (51.1%) | 392 (48.5%) | 200 (57.1%) | 0.007 |
ARNI, n (%) | 12 (1.0%) | 8 (1.0%) | 4 (1.1%) | 0.761 |
𝜷-Blocker, n (%) | 968 (83.6%) | 681 (84.3%) | 287 (82.0%) | 0.336 |
Statins, n (%) | 1,146 (99.0%) | 802 (99.3%) | 344 (98.3%) | 0.202 |
Antidiabetic agents, n (%) | 483 (41.7%) | 323 (40.0%) | 160 (45.7%) | 0.069 |